Context Therapeutics Inc. (NASDAQ:CNTX) Short Interest Update

Context Therapeutics Inc. (NASDAQ:CNTX) was the target of a large drop in short interest in November. As of November 30th, there was short interest totalling 802,800 shares, a drop of 8.7% from the November 15th total of 879,600 shares. Based on an average daily volume of 285,600 shares, the days-to-cover ratio is currently 2.8 days. Currently, 1.4% of the company’s stock are sold short.

Context Therapeutics Stock Performance

Shares of NASDAQ CNTX opened at $1.39 on Monday. The stock has a market cap of $104.25 million, a P/E ratio of -1.53 and a beta of 2.00. The firm has a 50 day moving average price of $1.84 and a 200 day moving average price of $2.04. Context Therapeutics has a 52-week low of $0.84 and a 52-week high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.11). Analysts predict that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CNTX has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Context Therapeutics in a report on Monday, September 23rd. D. Boral Capital began coverage on shares of Context Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating and a $9.00 price target on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Context Therapeutics currently has a consensus rating of “Buy” and an average price target of $6.80.

Hedge Funds Weigh In On Context Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Y Intercept Hong Kong Ltd bought a new stake in shares of Context Therapeutics in the 3rd quarter valued at $89,000. Renaissance Technologies LLC raised its holdings in Context Therapeutics by 63.4% during the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after acquiring an additional 25,300 shares during the period. State Street Corp lifted its position in shares of Context Therapeutics by 21.5% during the third quarter. State Street Corp now owns 111,907 shares of the company’s stock worth $219,000 after acquiring an additional 19,800 shares in the last quarter. Affinity Asset Advisors LLC boosted its holdings in shares of Context Therapeutics by 392.4% in the second quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after acquiring an additional 1,290,323 shares during the period. Finally, Franklin Resources Inc. purchased a new position in shares of Context Therapeutics in the third quarter valued at $3,689,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.